About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

351,441 studies
in
216 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 10/25/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 10/25/2020.
  • Janus Kinase 2 (JAK2)

    The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

     

    Janus kinases (JAKs) mediate the signaling of cytokine receptors. Under normal physiological conditions, JAK2 becomes activated following ligand binding. Activated JAK2 then activates the STAT proteins, which dimerize, translocate to the nucleus, and regulate the transcription of target genes, including genes that regulate the proliferation, survival and differentiation of hematopoietic cells.1 Myelofibrosis can be caused by alterations including mutant Calreticulin and MPL signaling, in the JAK/STAT pathway.2 Point mutations in JAK2 can also constitutively activate the JAK/STAT pathway, resulting in abnormal hematopoiesis and dysregulation of inflammatory signaling.2,3 JAK2V617F is the predominant driver mutation in myeloproliferative neoplasm (MPN) phenotypes, including polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis; however, this mutation in JAK is absent in some patients with these MPN subtypes.4-6 Investigations of JAK inhibitors further validate the central role of JAK2 in the pathophysiology of MPNs.7-9

    Used under license, ©2019 Impact Biomedicines, Inc.

    View Related Molecules

    References

    1. Vainchenker W, et al. F1000Res. 2018;7:82. PMID: 29399328
    2. Cazzola M and Kralovics R. Blood. 2014;123:3714-3719. PMID: 24786775
    3. Teferri A. Am J Hematol. 2016;91:1262-1271. PMID: 27870387
    4. Silvennoinen O, Hubbard SR. Blood. 2015;125(22):3388-3392. PMID: 25824690
    5. Staerk J, et al. J Biol Chem. 2005;280:41893-41899. PMID: 16239216
    6. Langabeer SE. JAKSTAT. 2016;5:e1248011. PMID: 28144498
    7. Tiedt R, et al. Blood. 2008:111:3931-3940. PMID: 18160670
    8. Kalota A, et al. Clin Cancer Res. 2013;19:1729-1730. PMID: 23386690
    9. Bose P, et al. Expert Opin Investig Drugs. 2017;26:723-734. PMID: 28441920